-葡萄糖同载体2抑制剂对冠状动脉微循环的作用
Shaoxin Chen1, Weiqian Ou1, Shuguang Gan1
1The Second People's Hospital of Foshan, Foshan, China.
Frontiers in pharmacology
|March 17, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂通过潜在地改善冠状动脉微血管功能障碍,显示出治疗心力衰竭的前景. 然而,仍然需要关于它们对冠状动脉微循环的影响的确证据.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状动脉微血管疾病 (CMVD) 是心力衰竭发展的关键因素.
- 冠状动脉微循环功能障碍是心力衰竭的一个重要致病机制.
- -葡萄糖共载体2 (SGLT2) 抑制剂用于心力衰竭,但其机制尚未完全理解.
研究的目的:
- 审查SGLT2抑制剂对冠状动脉微循环的影响.
- 阐明SGLT2抑制剂在心力衰竭中的药理机制.
- 为CMVD和心力衰竭治疗提供洞察力.
主要方法:
- 对SGLT2抑制剂和冠状动脉微循环的已完成和正在进行的实验进行审查.
- 对动物研究和临床试验的分析.
主要成果:
- SGLT2 抑制剂可能通过细胞过程 (如氧化应激和能量代谢) 影响CMVD.
- 动物研究表明,SGLT2抑制剂可以改善微循环功能障碍.
- 对SGLT2抑制剂对冠状动脉微循环的影响的临床试验结果不一致.
结论:
- 冠状动脉微血管功能障碍可能是SGLT2抑制剂在心力衰竭中的治疗点.
- 需要进一步的研究来确定SGLT2抑制剂对微循环功能障碍的影响的确证据.
相关概念视频
Glucose Transporters
22.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
Secondary Active Transport
6.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Glucose Absorption Into the Small Intestine
31.1K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.1K
Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153


